Windsor Capital Management’s Novartis NVS Stock Holding History

Windsor Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,595	Closed	-$131K	–	316
2015 Q3	$131K	Buy	+1,595	New	+$142K	0.08%	116
2014 Q1	–	Sell	-1,716	Closed	-$124K	–	220
2013 Q4	$124K	Buy	1,716 +120	+8%	+$8.34K	0.07%	104
2013 Q3	$110K	Hold	1,596	–	–	0.06%	117
2013 Q2	$101K	Buy	+1,596	New	+$104K	0.06%	103

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Institutional Capital Chicago, Illinois $6.75B AUM 3.51% 1-Year Est. Return

Windsor Capital Management's NVS Position: Q4 2015 in Review

Windsor Capital Management sold out of Novartis (NVS) in Q4 2015, closing a stake of 1,595 shares — an estimated $131K sold.

Windsor Capital Management first reported a position in NVS in Q2 2013 and held it in 4 quarters. The position peaked at $131K in Q3 2015. 927 funds tracked by Wall St. Rank hold NVS as of Q4 2015.

Windsor Capital Management reported no remaining Novartis position as of Q4 2015 after selling out during the quarter.
Windsor Capital Management sold 1,595 Novartis shares in Q4 2015, an estimated $131K.
Windsor Capital Management first reported a position in Novartis in Q2 2013 and held it in 4 quarters.
Windsor Capital Management's Novartis position peaked at $131K in Q3 2015.
927 funds tracked by Wall St. Rank held Novartis as of Q4 2015.

Based on Windsor Capital Management's 13F filing for Q4 2015, filed 1 Feb 2016.